P102 Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study
Attauabi, M.(1,2,3);Poulsen, A.(4);Kajbæk Verner-Andersen, M.(5);Rosager Hansen, M.(6);Pedersen, N.(7);Pilegaard Prahm, A.(4);Berg Lødrup, A.(8);Haderselv, K.(9);Larsen, L.(10);Jess, T.(10,11);Glerup, H.(12);Molazahi, A.(13);Mathiassen Oppfeldt, A.(14);Dahlerup, J.F.(15);Lodberg Hvas, C.(15);Neumann, A.(16);Wase, A.(16);Dam Jensen, M.(17);Nathan, T.(17);Jensen, S.(17);Theede, K.(1,3);Kiszka-Kanowitz, M.(1,3);Benedict Seidelin, J.(2);Burisch, J.(1,3);
(1)Hvidovre University Hospital, Gastrounit- Medical Section, Hvidovre, Denmark;(2)Herlev University Hospital, Department of Gastroenterology and Hepatology, Herlev, Denmark;(3)University of Copenhagen- Hvidovre Hospital, Copenhagen center for inflammatory bowel disease in children- adolescents and adults, Hvidovre, Denmark;(4)Bispebjerg University Hospital, Digestive Disease Center, Copenhagen, Denmark;(5)Zealand University Hospital, Department of Internal Medicine, Koege, Denmark;(6)North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark;(7)Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark;(8)Region Hospital West Jutland- Herning, Department of Internal Medicine, Herning, Denmark;(9)Rigshospitalet- Copenhagen University Hospital, Department of Gastroenterology, Copenhagen, Denmark;(10)Aalborg University Hospital, Department of Gastroenterology and Hepatology, Aalborg, Denmark;(11)Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark;(12)Region Hospital Silkeborg, Department of Internal Medicine, Silkeborg, Denmark;(13)Holbaek Hospital, Department of Internal Medicine, Holbaek, Denmark;(14)Region Hospital Horsens, Department of Internal Medicine, Horsens, Denmark;(15)Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark;(16)Region Hospital Viborg, Department of Internal Medicine, Viborg, Denmark;(17)Lillebaelt Hospital, Department of Internal Medicine- Section of Gastroenterology, Vejle, Denmark; the Danish COVID-IBD Study Group
Background
Population-based data regarding outcomes of coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Studies on the association of COVID-19 outcomes and immunomodulating therapies, are scarce. Therefore, we aimed to conduct a population-based study investigating the outcomes of COVID-19 among patients with UC and CD in Denmark.
Methods
The Danish COVID-19 IBD Database is an extensive population-based database that prospectively monitors the disease course of laboratory-confirmed COVID-19 among patients with UC and CD in Denmark. Severe COVID-19 was defined as COVID-19 necessitating intensive care unit admission, ventilator use, or death. Regression analysis was adjusted for age, sex, disease type, disease activity, cardiovascular disease, and corticosteroids.
Results
The study recruited 363 patients (UC: 223; CD: 140) from January 28th, 2020, to February 7th, 2021. A total of 36 (16.1%) and 18 (12.9%) patients with UC and CD, respectively, required a COVID-19 related hospitalization, while eight (3.6%) and three (2.1%) patients required intensive care treatment. Death due to COVID-19 was observed among eight (3.6%) and two (1.4%) patients, respectively. The association between these outcomes and IBD-related treatment is presented in Table 1. As shown, none of the IBD-related medications were associated with severe COVID-19 in univariate and adjusted analysis. However, systemic steroids were found to be associated with the risk of COVID-19 related hospital admission among patients with UC (adjusted odds ratio (aOR)=6.54 (95% CI 1.09-36.39)) and CD (aOR=5.45 (95% CI 2.07-12.24)).
Conclusion
This ongoing Danish population-based study on COVID-19 outcomes among patients with UC and CD demonstrated severe COVID-19 among only a minority of patients, which was not associated with IBD-related medications. However, use of systemic steroids were associated with COVID-19 necessitating hospital admission among patients with UC and CD.